Trame De Mise En Page D'une
Total Page:16
File Type:pdf, Size:1020Kb
Mid-Term Report 2020 DIRECTOR: DEPUTY DIRECTORS: Pr. Pierre LAURENT-PUIG Pr. Michaela FONTENAY Pr. Wolf-Hervé FRIDMAN SIRIC Designation 2018-2022 (Integrated Cancer Research SIte) Mid-term Report (2020) CARPEM : CAncer Research for SIRIC title PErsonnalized Medicine Director of the SIRIC Pierre Laurent-Puig Mailing address 45 rue des Saints Pères 75006 Paris Email [email protected] Phone number +33608437691 General manager of the SIRIC Yannick Ladeiro [email protected] Email +330624360931 Phone number First SIRIC designation date ☒2011/12 ☐2018 Mid-term report date 31 Aout 2020 TABLE OF CONTENT MID-TERM REPORT ................................................................................................. 1 INTRODUCTION ....................................................................................................... 1 1. ORGANISATION AND MANAGEMENT OF THE SIRIC ....................................... 1 1.1. Governance and managerial organisation .......................................................... 3 1.2. Scientific organisation .................................................................................... 3 1.2.1. Steering committee ...................................................................................... 3 1.2.2. Carpem council ............................................................................................ 4 1.2.3. Scientific advisory board ............................................................................... 4 1.2.4. Advisory translational ethics board (ATEB) ..................................................... 5 1.3. Managerial organisation for platforms and specific infrastructures ................ 5 1.4. Administrative and financial management ...................................................... 5 1.5. Role and contrib. of patient representatives/advocates in the SIRIC governance.. 5 1.6. Conclusion ...................................................................................................... 6 2. GLOBAL TRANSVERSAL ACTIONS SERVING ALL THE INTEGRATED RESEARCH PROGRAMMES ........................................................................................................ 7 2.1. Transversal platforms ...................................................................................... 7 2.1.1. Translational research platform..................................................................... 7 2.1.2. Genomics platform ....................................................................................... 7 2.1.3. Centre of histology, cell imaging and flow cytometry platform (chic) ............... 9 2.1.4. Pathological and immunomonitoring platform...............................................12 2.1.5. •animal housing facilities .............................................................................14 2.2. Biobanks/cohorts............................................................................................ 14 2.3. Databases ...................................................................................................... 16 2.4. Teams with specific expertises ......................................................................... 18 2.4.1. Translational bioinformatics and data integration team (anita burgun) ...........18 2.4.2. Medical ethics (marie france mamzer) ..........................................................18 2.4.3. Centre essai phase précoce - early phase trial center (cepec) .........................18 2.4.4. Nutritional epidemiology research team (mathilde touvier) ...........................19 2.5. Actions supporting emergence ......................................................................... 20 2.6. Actions supporting training ............................................................................. 21 2.6.1. Phds and master 2 .......................................................................................21 2.6.2. Post-doctoral research fellowships ...............................................................22 2.6.3. The inter-university diploma “molecular medecine in cancer” ........................23 3. INTEGRATED RESEARCH PROGRAMMES ...................................................... 24 A. INTEGRATED RESEARCH PROGRAM 1: METABOLISM, GENETICS, IMMUNITY & ENVIRONMENT ....................................................................................................... 24 3.1. Initial action plan ............................................................................................ 24 3.2. Achievements ................................................................................................. 25 3.3. Amendements to the original work plan ........................................................... 28 3.4. Outstanding performances and successful developments .................................. 28 3.5. Quality of the collaboration............................................................................. 29 3.5.1. Intrasiric collaboration.................................................................................29 3.5.2. Extrasiric collaboration ................................................................................30 3.6. Programmes for the dissemination of knowledge and good practices ................. 30 3.7. Impact of the SIRIC designation on the integrated research programme ............. 31 3.8. Action plan for the 2nd period of the designation ............................................. 31 B. INTEGRATED RESEARCH PROGRAM 2: CANCER HETEROGENEITY: A CHALLENGE FOR PATIENT MANAGEMENT ........................................................32 3.1. Initial action plan ............................................................................................ 32 3.2. Achievements ................................................................................................. 33 3.3. Amendements to the original work plan ........................................................... 40 3.4. Outstanding performances and successful developments .................................. 40 3.5. Quality of the collaboration............................................................................. 41 3.5.1. Intrasiric collaboration.................................................................................41 3.5.2. Extrasiric collaboration ................................................................................41 3.6. Programmes for the dissemination of knowledge and good practices ................. 43 3.7. Impact of the SIRIC designation on the integrated research programme ............. 44 3.8. Action plan for the 2nd period of the designation ............................................. 44 C. INTEGRATED RESEARCH PROGRAM 3: DYNAMIC CONSENT AND HEALTH DEMOCRACY ..................................................................................................46 3.1. Initial action plan ............................................................................................ 46 3.2. Achievements ................................................................................................. 47 3.3. Amendements to the original work plan ........................................................... 48 3.4. Outstanding performances and successful developments .................................. 48 3.5. Quality of the collaboration............................................................................. 49 3.5.1. Intrasiric collaboration.................................................................................49 3.5.2. Extrasiric collaboration ................................................................................50 3.6. Programmes for the dissemination of knowledge and good practices ................. 50 3.7. Impact of the SIRIC designation on the integrated research programme ............. 50 3.8. Action plan for the 2nd period of the designation ............................................. 50 4. GENERAL CONCLUSION OF THE MID-TERM REPORT .................................52 4.1. Added-value of the siric designation ................................................................ 52 4.2. General conclusion and action plan for the 2nd period of the SIRIC designation .. 52 5. ANNEXES ...............................................................................................53 EVALUATION CRITERIA....................................................................................85 MID-TERM REPORT ABSTRACT 1- Global vision of the SIRIC CARPEM brings together the oncology expertise of Université de Paris, Inserm and Assistance Publique – Hôpitaux de Paris. We are devoted to cancer research for personaliZed medicine. Our vision is that the collaboration within the same organisation of oncologists, hematologists, geneticists, immunologists and epidemiologists creates new knowledge to understand the mechanisms of cell transformation, to better classify tumors, define cancer prognosis and propose new therapeutic targets. Furthermore, to integrate the holistic perception of cancer transformation, we added the dimension of metabolism in our program. To reach our goals we created shared plateforms: a translational research plateform to integrate the different sources of data generated by the CARPEM clinical and research teams on the same cohort of patients. Information is stored in the CARPEM data warehouse and accessible to the community of CARPEM researchers thanks to the anonymization. We have engaged the creation of a cancer dedicated bioinformatic platform which will accelerate the analyses of large dataset of